Editor's Choice December 2011
Does breastfeeding protect against the development of eczema?
Oxygen saturation and perfusion changes during photodynamic therapy: use of noninvasive monitoring
Patient education about topical treatments
Predicting the unpredictable: autoantibody profile as parameter to foretell individual responses to infliximab treatment?
Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms
Systemic treatment of locally advanced nonmetastatic cutaneous squamous cell carcinoma: a review of the literature
Methylisothiazolinone contact allergy: a review
Hair greying is associated with active hair growth
Assessment of the health status of 2499 dermatological outpatients using the 12-item Medical Outcomes Study Short Form (SF-12) questionnaire
Increased immunoreactivity of membrane type-1 matrix metalloproteinase (MT1-MMP) and β-catenin in high-risk basal cell carcinoma
Evaluation of autologous plasma skin test in patients with chronic idiopathic urticaria
Tattoo inks in general usage contain nanoparticles
Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma
The influence of nitric oxide synthase 2 on cutaneous wound angiogenesis
Demonstration of autoantibodies against tyrosine hydroxylase in patients with alopecia areata
Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients
Blue-black rule: a simple dermoscopic clue to recognize pigmented nodular melanoma
Evaluation of the clinical efficacy of the 1450 nm laser in acne vulgaris: a randomized split-face, investigator-blinded clinical trial
Benign mucinous metaplasia of the genital mucosa: histomorphological and immunohistochemical features and criteria for differentiation from extramammary Paget disease
Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study
Lack of evidence for a protective effect of prolonged breastfeeding on childhood eczema: lessons from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two
Diffuse and focal palmoplantar keratoderma can be caused by a keratin 6c mutation
Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness
Absence of clinical and dermoscopic differences between congenital and noncongenital melanocytic naevi in a cohort of 2-year-old children
Misdiagnosis and delay in referral of children with localized scleroderma
Herlitz junctional epidermolysis bullosa: diagnostic features, mutational profile, incidence and population carrier frequency in the Netherlands
Oxygen saturation and perfusion changes during dermatological methylaminolaevulinate photodynamic therapy
Are we giving patients enough information on how to use topical treatments? Analysis of 767 prescriptions in psoriasis
Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study
Serotonin induces melanogenesis via serotonin receptor 2A
Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis
Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction
Treatment of notalgia paraesthetica with an 8% capsaicin patch
Patient-reported outcomes in psoriasis research and practice
Porphyria cutanea tarda and glucose metabolism alterations
Porphyria cutanea tarda and glucose metabolism alterations: reply from authors
Raynaud phenomenon, digital gangrene and hypergammaglobulinaemic purpura occurring in a patient with IgG4-related disease
News and Notices
Detection of copy number variants at new psoriasis loci identified by genome-wide association studies : FC-1
Replication of 18 psoriasis genetic associations in Caucasians : FC-2
A homozygous mutation of IL36RN gene leads to interleukin-36 receptor antagonist deficiency and causes generalized pustular psoriasis : FC-3
Genetic support for a role for the inflammasome in psoriasis : FC-4
Genetic and functional characterization of the RNF114 psoriasis susceptibility gene suggests a pathogenic role for the dysregulation of innate antiviral immunity : FC-5
Expression of late cornified envelope ( LCE ) genes indicates a role for insufficient skin barrier repair in pathogenesis of psoriasis : FC-6
Functional investigation of the psoriasis protective IL23R R381Q gene variant reveals impaired interleukin-23-induced Th17 response : FC-7
HLA-B *27 and HLA-C *0602 are risk alleles for psoriatic arthritis among psoriasis patients : FC-8
Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than psoriasis cases with normal nails: a novel explanation for why nail disease predicts arthropathy : FC-9
Human epidermal Langerhans cells replenish skin xenografts and are depleted by alloreactive T cells in vivo: a model to study psoriasis : FC-10
Systematic review of the incidence and prevalence of psoriasis : FC-11
Reconstructed human skin populated with activated T cells: a new in vitro model for psoriasis : FC-12
Interleukin-17A is an essential cytokine to sustain pathogenic cell activation and inflammatory gene circuits in psoriasis vulgaris : FC-13
Streptococcus induces simultaneous Th1, Th17, Th22 responses, and epidermal cell activation/hyperplasia in vivo, through the interaction of circulating CLA+ T cells and autologous epidermal cells in psoriasis : FC-14
Single-cell analysis confirms antigen-specific clonal T-cell expansions within psoriatic skin lesions : FC-15
Regulation and functional impact of novel interleukin-1 family members in psoriatic inflammation : FC-16
Interleukin-19 is a novel component of the immunological cascades in psoriasis : FC-17
Jak/STAT expression and activation in psoriasis : FC-18
CT327: a novel breakthrough therapy targeting the NGF/TrkA kinase pathway in psoriasis : FC-19
TNFAIP3 polymorphisms and age at onset are associated with response to tumour necrosis factor blockade in psoriasis : FC-20
Results of a single ascending dose study to assess the safety and tolerability of CNTO 1959 following intravenous or subcutaneous administration in healthy subjects and in subjects with moderate to severe psoriasis : FC-21
Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17R expression and signalling : FC-22
Presence of HLA-Cw6 but not LCE3C_LCE3B deletion influences clinical response to ustekinumab in psoriasis patients : FC-23
Evaluation of the effect of pulsed-dye laser on chronic psoriatic plaque using vascular endothelial growth factor as a parameter : P-1
Effect of methotrexate and psoralen plus ultraviolet A on the amount of vascular endothelial growth factor expression and capillary perfusion of psoriatic lesions : P-2
The association between endoplasmic reticulum stress genes and psoriasis : P-3
α-Melanocyte-stimulating hormone generates functional regulatory T cells able to suppress pathogenic effector cells in murine and human psoriasis : P-4
Antitumour necrosis factor-α treatment ameliorates psoriasis by inducing functional regulatory T cells : P-5
Activation of protein kinase C-α in keratinocytes may explain valrubicin effect on psoriasis amelioration : P-6
Topical valrubicin application reduces acute and chronic skin inflammation in murine models : P-7
Noninvasive monitoring of psoriasis : P-8
Quality of life and health-state utilities in patients with psoriasis at the National Skin Centre, Singapore : P-9
YKL-40: a potential biomarker for psoriatic arthritis? : P-10
Psoriasis comorbidities: a 5-year retrospective study : P-11
Therapeutic response to tumour necrosis factor-α blockade in psoriasis is associated with increased peripheral and reduced lesional regulatory T cells and an inhibition of Th1 and Th17 cells : P-12
Immunogenicity of tumour necrosis factor inhibitors in patients with psoriasis receiving long-term treatment : P-13
MicroRNA signature of glucocorticoid treatment in patients with psoriasis can be translated to a human xenograft mouse model : P-14
Tuberculin skin test as a tool for detecting latent tuberculosis in patients with psoriasis in a highly endemic setting : P-15
Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis : P-16
A Phase 2 trial of LY2439821, an anti-interleukin-17 monoclonal antibody, given subcutaneously in patients with moderate to severe psoriasis : P-17
Biologics control platelet activation throughout 12 months treatment of chronic plaque poriasis : P-18
Do methotrexate polyglutamates have a role as a biomarker of clinical response to methotrexate in psoriasis? : P-19
Tumour necrosis factor antagonists selectively downregulate the Th17 response in psoriasis : P-20
Can stress reduction techniques improve the clinical severity of psoriasis? A systematic review : P-21
South Asian perspectives about living with psoriasis: a qualitative U.K. study : P-22
Adalimumab treatment for moderate to severe psoriasis substantially improves Psoriasis Area and Severity Index (PASI) scores as analysed by body region and individual PASI component: subanalysis from the CHAMPION study : P-23
Our experience using ustekinumab in patients with plaque psoriasis : P-24
Dysregulated production of interleukin-23 by Langerhans cells from patients with psoriasis : P-25
Identification of further TRAF3IP2 coding variants in patients with psoriatic arthritis and functional characterization : P-26
Cardiovascular biomarkers in patients with psoriasis : P-27
Understanding treatment decision-making in people with psoriasis using the necessity-concerns framework : P-28
Identification of triptolide as a potential aryl hydrocarbon receptor antagonist in memory T cells : P-29
Inhibition of differentiation of human Th17 cells by dexamethasone, vitamin D3 and triptolide: a comparative study : P-30
A novel human psoriatic skin equivalent: the importance of transit amplifying keratinocytes : P-31
An Investigation of late-onset psoriasis : P-32
Adherence in psoriasis: a systematic narrative review : P-33
The path from psoriasis to psoriatic arthritis: a switch to a vascular phenotype at sites of subclinical enthesopathy could be relevant in the dermatological setting to predict psoriatic arthritis development : P-34
Perturbations in gene expression and inflammatory cell subsets in the peripheral blood of patients with psoriasis : P-35
Comprehensive analysis of dendritic cell subsets in chronic skin lesions of atopic dermatitis and psoriasis : P-36
Decreased level of inflammation- and autoimmunityrelated microRNAs in serum of patients with psoriasis after antitumour necrosis factor-α therapy : P-37
Characterization of skin resident T cells during different phases of psoriasis : P-38
Antioxidants have possible therapeutic activity for psoriasis : P-39
Psoriasis following bariatric surgery: clinical evolution and impact on quality of life in 10 patients : P-40
Metabolic characteristics in Chilean patients with psoriasis : P-41
Gene environment interaction in psoriasis and psoriatic arthritis: smoking and HLA-C*0602 : P-42
Longitudinal effects of active therapy in a clinical trial on Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System-Physician's Global Assessment for assessing severity of psoriasis : P-43
Immunological changes in patients with psoriasis under long-term treatment with fumaric acid esters : P-44
Distribution and appearance of antimicrobial peptides, neuropeptides and inflammatory markers in psoriatic lesions : P-45
Plasma adiponectin level is correlated with body mass index and duration of disease, but not to the Psoriasis Area and Severity Index, in patients with psoriasis : P-46
Interleukin-4 inhibits proinflammatory response in epidermal cells : P-47
Studies on abnormal keratinocyte functions in the early steps of psoriasis pathomechanism : P-48
PRINS, the psoriasis susceptibility related noncoding RNA regulates the ultraviolet B-induced intracellular shuttling of nucleophosmin : P-49
Study of functional molecules on regulatory T cells in human psoriasis blood and skin : P-50
The impact of writing exercises on quality of life in patients with psoriasis undergoing systemic treatments : P-51
Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis : P-52
Follow-up on the effect of a patient educational programme: early results of a prospective randomized controlled trial in psoriasis and atopic dermatitis : P-53
The illness experience in patients with psoriasis: suggestions for strategies to develop quality of care : P-54
The impact of obesity on psoriasis : P-55
Field performance of the Skindex-17 quality of life questionnaire: a comparison with the Skindex-29 in a sample of 220 outpatients with psoriasis and 2267 with other skin conditions : P-57
Clinically effective ustekinumab treatment suppresses serum β-defensin-2 levels but does not inhibit the local skin antimicrobial response : P-59
Caspase-5: a regulator of inflammation? : P-60
Interleukin-17C expression is regulated by a p38 MAPK- and NF-κB-dependent mechanism in cultured human keratinocytes : P-61
STAT1 expression and activation is increased in lesional psoriatic skin : P-62
Patients with moderate/severe psoriasis report overall work impairment, with improvement on etanercept therapy: results from the PRISTINE study : P-63
Mixed treatment comparison of infliximab with ustekinumab in patients with moderate to severe psoriasis : P-64
Specific and overlapping functions of T-cell mediators in psoriasis pathogenesis : P-65
Immunological biomarker discovery in psoriasis using an advanced flow cytometry platform : P-66
Production modi of interleukin-22 : P-67
Role of interleukin-24 in psoriasis pathogenesis : P-68
Survey of comorbidities in patients with psoriasis in Slovakia : P-69
Control of psoriasis-like skin inflammation by epidermal keratinocytes through a tumour necrosis factor-α- and interleukin-24-dependent mechanism : P-70
Use of tumour necrosis factor-α antagonist in a patient with psoriasis and Chagas disease: a case report : P-71
A snapshot of in vivo occurring pathogenic lymphocytes in psoriasis : P-72
Psoriasis and the extracellular matrix : P-73
Exome sequencing identifies rare recessive IL1F5 variants in generalized pustular psoriasis : P-74
Paradoxic psoriasis induced by antitumour necrosis factor treatment: a report of nine cases and evidence for a new pathogenic mechanism : P-75